|
1
|
Moura FA, de Andrade KQ, Dos Santos JCF,
Araújo ORP and Goulart MOF: Antioxidant therapy for treatment of
inflammatory bowel disease: Does it work? Redox Biol. 6:617–639.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suh JH and Saba JD:
Sphingosine-1-phosphate in inflammatory bowel disease and
colitis-associated colon cancer: The fat's in the fire. Transl
Cancer Res. 4:469–483. 2015.PubMed/NCBI
|
|
3
|
Yang QF, Chen BL, Zhang QS, Zhu ZH, Hu B,
He Y, Gao X, Wang YM, Hu PJ, Chen MH and Zeng ZR: Contribution of
MDR1 gene polymorphisms on IBD predisposition and response to
glucocorticoids in IBD in a Chinese population. J Dig Dis.
16:22–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eichele DD and Kharbanda KK: Dextran
sodium sulfate colitis murine model: An indispensable tool for
advancing our understanding of inflammatory bowel diseases
pathogenesis. World J Gastroenterol. 23:6016–6029. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang ZL, Fan HY, Yang MY, Zhang ZK and
Liu K: Therapeutic effect of a hydroxynaphthoquinone fraction on
dextran sulfate sodium-induced ulcerative colitis. World J
Gastroenterol. 20:15310–15318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Däbritz J, Gerner P, Enninger A, Classen M
and Radke M: Inflammatory bowel disease in childhood and
adolescence. Dtsch Arztebl Int. 114:331–338. 2017.PubMed/NCBI
|
|
7
|
Balfe A, Lennon G, Lavelle A, Docherty NG,
Coffey JC, Sheahan K, Winter DC and O'Connell PR: Isolation and
gene expression profiling of intestinal epithelial cells: Crypt
isolation by calcium chelation from in vivo samples. Clin Exp
Gastroenterol. 11:29–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Biasi F, Leonarduzzi G, Oteiza PI and Poli
G: Inflammatory bowel disease: Mechanisms, redox considerations,
and therapeutic targets. Antioxid Redox Signal. 19:1711–1747. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yarlas A, D'Haens G, Willian MK and Teynor
M: Health-related quality of life and work-related outcomes for
patients with mild-to-moderate ulcerative colitis and remission
status following short-term and long-term treatment with
multimatrix mesalamine: A prospective, open-label study. Inflamm
Bowel Dis. 24:450–463. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oliveira L and Cohen RD: Maintaining
remission in ulcerative colitis-role of once daily extended-release
mesalamine. Drug Des Devel Ther. 5:111–116. 2011.PubMed/NCBI
|
|
11
|
Ming LR, Wu Bin W and Tang Yao T: Safety
and effectiveness of mesalazine in the treatment of ulcerative
colitis: A systematic review. China Pharm. 21:4201–4204. 2010.
|
|
12
|
Algaba A, Guerra I, García García de
Paredes A, Hernández Tejero M, Ferre C, Bonillo D, Aguilera L,
López-Sanromán A and Bermejo F: What is the real-life maintenance
mesalazine dose in ulcerative colitis? Rev Esp Enferm Dig.
109:114–121. 2017.PubMed/NCBI
|
|
13
|
Ransford RA and Langman MJ: Sulphasalazine
and mesalazine: Serious adverse reactions re-evaluated on the basis
of suspected adverse reaction reports to the Committee on Safety of
Medicines. Gut. 51:536–539. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimodate Y, Takanashi K, Waga E, Fujita
T, Katsuki S and Nomura M: Exacerbation of bloody diarrhea as a
side effect of mesalamine treatment of active ulcerative colitis.
Case Rep Gastroenterol. 5:159–165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sehgal P, Colombel JF, Aboubakr A and
Narula N: Systematic review: Safety of mesalazine in ulcerative
colitis. Aliment Pharmacol Ther. 47:1597–1609. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vaughn BP and Moss AC: Novel treatment
options for ulcerative colitis. Clin Investig (Lond). 3:1057–1069.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takei M: Development of polaprezinc
research. Yakugaku Zasshi. 132:271–277. 2012.(In Japanese).
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Itagaki M, Saruta M, Saijo H, Mitobe J,
Arihiro S, Matsuoka M, Kato T, Ikegami M, Tajiri H and Scand J:
Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in
patients with ulcerative colitis. Scand J Gastroenterol. 49:164–72.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ko JK and Leung CC: Ginger extract and
polaprezinc exert gastroprotective actions by anti-oxidant and
growth factor modulating effects in rats. J Gastroenterol Hepatol.
25:1861–1868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakae K and Yanagisawa H: Oral treatment
of pressure ulcers with polaprezinc (zinc L-carnosine complex):
8-week open-label trial. Biol Trace Elem Res. 158:280–288. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feldman AT and Wolfe D: Tissue processing
and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chassaing B, Aitken JD, Malleshappa M and
Vijay-Kumar M: Dextran sulfate sodium (DSS)-induced colitis in
mice. Curr Protoc Immunol. 104:Unit 15.25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Y, Okamura S, Kudo T, Masuo T and
Mori M: Calcineurin inhibition by polaprezinc in rats with
experimentally-induced colitis. Life Sci. 88:432–439. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsukura T and Tanaka H: Applicability of
zinc complex of L-carnosine for medical use. Biochemistry (Mosc).
65:817–823. 2000.PubMed/NCBI
|
|
25
|
Ohkawara T, Nishihira J, Nagashima R,
Takeda H and Asaka M: Polaprezinc protects human colon cells from
oxidative injury induced by hydrogen peroxide: Relevant to
cytoprotective heat shock proteins. World J Gastroenterol.
12:6178–6181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Itagaki M, Saruta M, Saijo H, Mitobe J,
Arihiro S, Matsuoka M, Kato T, Ikegami M and Tajiri H: Efficacy of
zinc-carnosine chelate compound, Polaprezinc, enemas in patients
with ulcerative colitis. Scand J Gastroenterol. 49:164–172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong Z, Du L, Xu X, Yang Y, Wang H, Qu A,
Qu X and Wang C: Aberrant expression of circulating Th17, Th1 and
Tc1 cells in patients with active and inactive ulcerative colitis.
Int J Mol Med. 31:989–997. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Murakami-Nakayama M, Tsubota M, Hiruma S,
Sekiguchi F, Matsuyama K, Kimura T, Moriyama M and Kawabata A:
Polaprezinc attenuates cyclophosphamide-induced cystitis and
related bladder pain in mice. J Pharmacol Sci. 127:223–228. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McDaniel DK, Eden K, Ringel VM and Allen
IC: Emerging roles for noncanonical NF-κB signaling in the
modulation of inflammatory bowel disease pathobiology. Inflamm
Bowel Dis. 22:2265–2279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kruis W, Kiudelis G and Racz I: Once daily
versus three times daily mesalazine granules in active ulcerative
colitis: A doube-blind, double-dummy, randomized, non-inferiority
trial. Gut. 58:233–237. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sanchez-Munoz F, Dominguez-Lopez A and
Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel
disease. World J Gastroenterol. 14:4280–4288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao X, Li J, Meng Y, Cao M and Wang J:
Treatment effects of jinlingzi powder and its extractive components
on gastric ulcer induced by acetic acid in rats. Evid Based
Complement Alternat Med. 2019:73658412019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fausel R and Afzali A: Biologics in the
management of ulcerative colitis-comparative safety and efficacy of
TNF-α antagonists. Ther Clin Risk Manag. 11:63–73. 2015.PubMed/NCBI
|
|
34
|
Arrigo P: Pathology-dependent effects
linked to small heat shock proteins expression: An Update.
Scientifica (Cairo). 2012:1856412012.PubMed/NCBI
|
|
35
|
Gupta R, Chaudhary AR, Shah BN, Jadhav AV,
Zambad SP, Gupta RC, Deshpande S, Chauthaiwale V and Dutt C:
Therapeutic treatment with a novel hypoxia-inducible factor
hydroxylase inhibitor (TRC160334) ameliorates murine colitis. Clin
Exp Gastroenterol. 7:13–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moghadamtousi SZ, Rouhollahi E, Karimian
H, Fadaeinasab M, Abdulla MA and Kadir HA: Gastroprotective
activity of Annona muricata leaves against ethanol-induced gastric
injury in rats via Hsp70/Bax involvement. Drug Des Devel Ther.
8:2099–2110. 2014.PubMed/NCBI
|
|
37
|
Ono K, Nimura S, Hideshima Y, Nabeshima K
and Nakashima M: Orally administered sodium 4-phenylbutyrate
suppresses the development of dextran sulfate sodium-induced
colitis in mice. Exp Ther Med. 14:5485–5490. 2017.PubMed/NCBI
|
|
38
|
Yu Q, Mao R, Lian L, Ng SC, Zhang S, Chen
Z, Zhang Y, Qiu Y, Chen B, He Y, et al: Surgical management of
inflammatory bowel disease in China: A systematic review of two
decades. Intest Res. 14:322–332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhai H, Liu A, Huang W, Liu X, Feng S, Wu
J, Yao Y, Wang C, Li Q, Hao Q, et al: Increasing rate of
inflammatory bowel disease: A 12-year retrospective study in
NingXia, China. BMC Gastroenterol. 16:22016. View Article : Google Scholar : PubMed/NCBI
|
